gptkbp:instance_of
|
gptkb:vaccine
|
gptkbp:administered_by
|
gptkb:horse_race
|
gptkbp:approves
|
gptkb:2012
gptkb:Australia
|
gptkbp:booster_required
|
yes
|
gptkbp:clinical_trial
|
conducted
prevention of Hendra virus infection
|
gptkbp:contraindication
|
none known
|
gptkbp:developed_by
|
gptkb:Zoetis
|
gptkbp:dosage_form
|
1 m L
|
gptkbp:formulation
|
injection
|
https://www.w3.org/2000/01/rdf-schema#label
|
Equivac He V
|
gptkbp:is_effective_against
|
high
|
gptkbp:is_vulnerable_to
|
gptkb:educational_campaigns
ongoing
government and private sectors
refrigerated
veterinary clinics
varies by provider
involves local stakeholders
based on research
between government and industry
based on risk assessment
advancements in veterinary medicine
trained personnel required
inactivated virus
contributes to global disease control
post-vaccination observation recommended
reduces Hendra virus outbreaks
reduces risk of disease
by Australian Pesticides and Veterinary Medicines Authority
|
gptkbp:manufacturer
|
gptkb:Zoetis_Australia_Pty_Ltd.
|
gptkbp:regulatory_compliance
|
registered
|
gptkbp:route_of_administration
|
subcutaneous
|
gptkbp:safety
|
generally safe
|
gptkbp:service_frequency
|
gptkb:annually
|
gptkbp:side_effect
|
mild swelling
|
gptkbp:storage
|
2-8° C
|
gptkbp:targets
|
gptkb:Equus_caballus
gptkb:Hendra_virus
|
gptkbp:type
|
equine vaccine
|
gptkbp:vaccine_adverse_reactions
|
rare
|
gptkbp:vaccine_category
|
preventive vaccine
|
gptkbp:vaccine_efficacy_studies
|
peer-reviewed
|
gptkbp:vaccine_ethics
|
considerations in development
|
gptkbp:vaccine_impact_studies
|
ongoing research
|
gptkbp:vaccine_label
|
contains instructions
|
gptkbp:vaccine_legislation
|
mandatory in some regions
|
gptkbp:vaccine_public_health
|
important for equine and human health
|
gptkbp:vaccine_research_institutions
|
collaborative efforts
|
gptkbp:vaccine_shelf_life
|
2 years
|
gptkbp:vaccine_usage
|
in endemic areas
|
gptkbp:bfsParent
|
gptkb:Hendra_virus
|
gptkbp:bfsLayer
|
7
|